Literature DB >> 7589584

Expression, purification, and characterization of the cGMP-dependent protein kinases I beta and II using the baculovirus system.

D Pöhler1, E Butt, J Meissner, S Müller, M Lohse, U Walter, S M Lohmann, T Jarchau.   

Abstract

Detailed studies of differences in distinct cGMP kinase isoforms are highly dependent on expression of large amounts of these enzyme isoforms that are not easily purified by conventional methods. Here cGMP-dependent protein kinases, the type I beta soluble form from human placenta, and the type II membrane-associated form from rat intestine, were each expressed in a baculovirus/Sf9 cell system and purified in milligram amounts by affinity chromatography. The expressed recombinant proteins displayed characteristics like those of their native counterparts. cGK I beta was expressed as a 76 kDa protein predominantly found in the cytosol fraction, whereas cGK II was expressed as an 86 kDa protein predominantly associated with the membrane fraction. The apparent Ka and Vmax of cGMP for activation of cGK I beta were 0.5 microM and 3.4 mumol/min/mg, and for cGK II were 0.04 microM and 1.8 mumol/min/mg.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589584     DOI: 10.1016/0014-5793(95)01168-e

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Selectivity in enrichment of cAMP-dependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins.

Authors:  Thin Thin Aye; Shabaz Mohammed; Henk W P van den Toorn; Toon A B van Veen; Marcel A G van der Heyden; Arjen Scholten; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2008-12-31       Impact factor: 5.911

2.  Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation.

Authors:  A B Vaandrager; A Smolenski; B C Tilly; A B Houtsmuller; E M Ehlert; A G Bot; M Edixhoven; W E Boomaars; S M Lohmann; H R de Jonge
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells.

Authors:  Stepan Gambaryan; Elke Butt; Anna Kobsar; Joerg Geiger; Natalia Rukoyatkina; Rimma Parnova; Viacheslav O Nikolaev; Ulrich Walter
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Atrial natriuretic peptide-stimulated Ca2+ reabsorption in rabbit kidney requires membrane-targeted, cGMP-dependent protein kinase type II.

Authors:  J G Hoenderop; A B Vaandrager; L Dijkink; A Smolenski; S Gambaryan; S M Lohmann; H R de Jonge; P H Willems; R J Bindels
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Structural Basis of Analog Specificity in PKG I and II.

Authors:  James C Campbell; Philipp Henning; Eugen Franz; Banumathi Sankaran; Friedrich W Herberg; Choel Kim
Journal:  ACS Chem Biol       Date:  2017-08-22       Impact factor: 5.100

6.  Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway.

Authors:  M Suhasini; H Li; S M Lohmann; G R Boss; R B Pilz
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

7.  Interaction of cCMP with the cGK, cAK and MAPK Kinases in Murine Tissues.

Authors:  Stefanie Wolfertstetter; Jörg Reinders; Frank Schwede; Peter Ruth; Elisabeth Schinner; Jens Schlossmann
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

8.  Nitric oxide targets oligodendrocytes and promotes their morphological differentiation.

Authors:  Giti Garthwaite; Kathryn Hampden-Smith; Gary W Wilson; David A Goodwin; John Garthwaite
Journal:  Glia       Date:  2014-10-18       Impact factor: 7.452

9.  Selective inhibition of intestinal guanosine 3',5'-cyclic monophosphate signaling by small-molecule protein kinase inhibitors.

Authors:  Marcel J C Bijvelds; Gary Tresadern; Ann Hellemans; Karine Smans; Natascha D A Nieuwenhuijze; Kelly F Meijsen; Jean-Pierre Bongartz; Luc Ver Donck; Hugo R de Jonge; Jan A J Schuurkes; Joris H De Maeyer
Journal:  J Biol Chem       Date:  2018-04-13       Impact factor: 5.157

10.  cGMP-Dependent Protein Kinase Inhibitors in Health and Disease.

Authors:  Stefanie Wolfertstetter; Johannes P Huettner; Jens Schlossmann
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.